Dr. Hassan Shora is a senior researcher at Port-Said university, member of supervising committee of PhD and MSc theses in molecular medicine cooperating with staff of department of biochemistry and molecular biology at faculty of science. He attained Harvard Medical School Associate in advanced Research training in 2020. He also is the Head of medicine & Director of diabetes center at Ismailia Medical Complex and works as a senior lecturer, Egyptian Board of physicians to train medical residents in Ismailia, Egypt. Dr. Shora is awarded Physician Recognition Award of The American Medical Association in 2003 and 2007. He published his first paper in 1984 while he was a second year undergraduate student and published several original research papers thereafter in international journals in role of adiponectin and glycemic control in delaying subclinical atherosclerotic changes in type 1 diabetics,
Dr. Hassan Shora
Egypt
markers of subclinical atherosclerosis in type 1 diabetics, visceral fat and liver size as determinants of subclinical atherosclerosis in type 1 diabetic adolescents, inflammatory biomarkers of cardiometabolic risk in obese type 2 diabetics iron binding stores in correlation with cardiometabolic risk in obese type 2 diabetics and NT Pro PNB as a marker of microvascular complications in type 2 diabetes.
Adiponectin, adipose tissue, obesity, atherosclerosis, diabetic microvascular complications, cardiometabolic risk, novel anti-inflammatory therapies Moab, for CVD prevention.
Please provide feedback by Clicking here